Cytokinetics(US:CYTK) Globenewswire·2025-11-11 12:50Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Incorporated for allegedly making false and misleading statements regarding the expected FDA approval of aficamten, which could impact investor confidence and stock performance [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, with a deadline for participation set for November 17, 2025 [2]. - The complaint alleges that Cytokinetics misled investors by claiming that FDA approval for aficamten was expected in the second half of 2025, while failing to submit a necessary Risk Evaluation and Mitigation Strategy (REMS) [2]. Company Statements - Cytokinetics admitted to not submitting the REMS despite having multiple pre-NDA meetings with the FDA regarding risk mitigation, which indicates that the company's public statements were materially misleading [2]. Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Registered shareholders will receive updates through a portfolio monitoring software at no cost [3]. Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].